What is Vallon Pharmaceuticals, Inc.'s current stock price?

Vallon Pharmaceuticals, Inc. (VLON) currently trades at USD 0.4000. Track real-time price changes and historical performance on AllInvestView.

What sector is Vallon Pharmaceuticals, Inc. in?

Vallon Pharmaceuticals, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Vallon Pharmaceuticals, Inc. VLON · Stock Open Vallon Pharmaceuticals, Inc. in new tab

0.4000 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Vallon Pharmaceuticals, Inc. (VLON)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Vallon Pharmaceuticals, Inc. Analysis (VLON)

United States Health Care Official Website Stock

Is Vallon Pharmaceuticals, Inc. a good investment? Vallon Pharmaceuticals, Inc. (VLON) is currently trading at 0.4000 USD.

Investor FAQ

Does Vallon Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vallon Pharmaceuticals, Inc.?

Vallon Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Exchange Ticker

NMS (United States) VLON

Trades

No dividend information available for this instrument.

Vallon Pharmaceuticals, Inc. VLON · Stock Open Vallon Pharmaceuticals, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Vallon Pharmaceuticals, Inc. Analysis (VLON)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Vallon Pharmaceuticals, Inc. VLON · Stock Open Vallon Pharmaceuticals, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Vallon Pharmaceuticals, Inc. Analysis (VLON)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications